WO2007041502A3 - Procedes pour la determination de la sensibilite a la therapie cancereuse - Google Patents

Procedes pour la determination de la sensibilite a la therapie cancereuse Download PDF

Info

Publication number
WO2007041502A3
WO2007041502A3 PCT/US2006/038451 US2006038451W WO2007041502A3 WO 2007041502 A3 WO2007041502 A3 WO 2007041502A3 US 2006038451 W US2006038451 W US 2006038451W WO 2007041502 A3 WO2007041502 A3 WO 2007041502A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cancer therapy
determining responsiveness
molecular tags
binding
Prior art date
Application number
PCT/US2006/038451
Other languages
English (en)
Other versions
WO2007041502A2 (fr
Inventor
Chris Petropoulos
Mike Bates
Colombe Chappey
Sharat Singh
Ali Mukherjee
Mengxiang Tang
Original Assignee
Monogram Biosciences
Chris Petropoulos
Mike Bates
Colombe Chappey
Sharat Singh
Ali Mukherjee
Mengxiang Tang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monogram Biosciences, Chris Petropoulos, Mike Bates, Colombe Chappey, Sharat Singh, Ali Mukherjee, Mengxiang Tang filed Critical Monogram Biosciences
Publication of WO2007041502A2 publication Critical patent/WO2007041502A2/fr
Publication of WO2007041502A3 publication Critical patent/WO2007041502A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Dans certains aspects, la présente invention a trait à des procédés et des compositions pour déterminer si une cellule cancéreuse est susceptible de réagir à un traitement avec un agent activité Her2. De préférence, les procédés de l'invention sont mis en oeuvre à l'aide d'ensembles de composés de liaison ayant des étiquettes moléculaires libérables qui sont spécifiques pour de constituants multiples d'un ou de plusieurs types de dimères. Suite à la liaison, les étiquettes moléculaires sont libérées et séparées du mélange de dosage pour analyse.
PCT/US2006/038451 2005-09-30 2006-09-29 Procedes pour la determination de la sensibilite a la therapie cancereuse WO2007041502A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72270905P 2005-09-30 2005-09-30
US60/722,709 2005-09-30

Publications (2)

Publication Number Publication Date
WO2007041502A2 WO2007041502A2 (fr) 2007-04-12
WO2007041502A3 true WO2007041502A3 (fr) 2007-10-25

Family

ID=37906799

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/038451 WO2007041502A2 (fr) 2005-09-30 2006-09-29 Procedes pour la determination de la sensibilite a la therapie cancereuse

Country Status (1)

Country Link
WO (1) WO2007041502A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9110066B2 (en) 2009-01-15 2015-08-18 Laboratory Corporation Of America Holdings HER-3 antibodies and methods of use

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2129396T1 (sl) 2007-02-16 2013-12-31 Merrimack Pharmaceuticals, Inc. Protitelesa proti ErbB3 in njihove uporabe
CA2711843C (fr) * 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Procedes de diagnostic du her-2
EP2313780B1 (fr) * 2008-07-08 2015-05-20 George Mason Research Foundation, Inc. C-erbb2 phosphorylé en tant que marqueur théranostique prédictif supérieur pour le diagnostic et le traitement du cancer
EA022884B1 (ru) 2008-08-15 2016-03-31 Мерримак Фармасьютикалз, Инк. СПОСОБ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ С ИСПОЛЬЗОВАНИЕМ АНТИ-ErbB3 АНТИТЕЛА
SG177252A1 (en) 2008-12-01 2012-03-29 Lab Corp America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
DK2544680T3 (en) 2010-03-11 2015-04-27 Merrimack Pharmaceuticals Inc USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
EP3087394A2 (fr) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050130238A1 (en) * 2003-04-01 2005-06-16 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050130238A1 (en) * 2003-04-01 2005-06-16 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TOVEY ET AL.: "Can Molecular Markers Predict When to Implement Treatment with Aromatase Inhibitors in Invasive Breast Cancer?", CLIN. CANCER RES., vol. 11, no. 13, July 2005 (2005-07-01), pages 4835 - 4842 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9110066B2 (en) 2009-01-15 2015-08-18 Laboratory Corporation Of America Holdings HER-3 antibodies and methods of use

Also Published As

Publication number Publication date
WO2007041502A2 (fr) 2007-04-12

Similar Documents

Publication Publication Date Title
WO2007041502A3 (fr) Procedes pour la determination de la sensibilite a la therapie cancereuse
WO2009005809A3 (fr) Compositions et procédés de traitement et de diagnostic d'un cancer
EA201001242A1 (ru) ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ
WO2005076743A3 (fr) Molecules de disaccharide et leurs derives et procedes d'utilisation associes
WO2007079164A3 (fr) Inhibiteurs de protéines kinases
WO2006020060A3 (fr) Composes de liaison aux proteines iap
WO2006009765A3 (fr) Procedes d'identification et d'utilisation de composes adaptes au traitement de cellules cancereuses resistantes aux medicaments
WO2008133722A3 (fr) Anticorps et diagnostics
WO2008064351A3 (fr) (r)-n-stéréoisomères d'analogues 4,5-époxy-morphinanium saturé en position 7 et 8
EP2476679A3 (fr) Triazoles substitués utilisés comme inhibiteurs AXL
GB0525041D0 (en) Methods, assays and compositions for treating retinol-related diseases
EP3311818A3 (fr) Inhibiteurs de tyrosine-kinase de bruton pour le traitement de tumeurs solides
WO2009006389A3 (fr) Composés utiles en tant qu'inhibiteurs de la kinase raf
WO2007086904A3 (fr) Compositions a utiliser dans l’identification d’adenovirus
WO2007064872A3 (fr) Composes de l'uree utilises dans le traitement du cancer
NO20076003L (no) TGF-beta 1 spesifikke antistoffer
EA201001223A1 (ru) Стабилизированные белковые композиции
WO2007064945A3 (fr) Therapies contre le cancer et compositions pharmaceutiques utilisees dans ces therapies
WO2008083367A3 (fr) Triazoles substitués par hétéroaryle polycyclique utiles comme inhibiteurs de axl
WO2004035747A3 (fr) Anticorps humains neutralisant anti-ifn-$g(g) utiles comme inhibiteurs selectifs du mecanisme d'action d'ifn-gamma
WO2006102504A3 (fr) Combinaisons destinees au traitement de cancer
BRPI0607306A2 (pt) derivados de quinoxalina como agentes anti-tumor
WO2007061939A3 (fr) Dérivés de métabolites de l'inhibiteur de hdac fk228
WO2010031056A3 (fr) Procédés et compositions pour moduler l'activité ire1, src, et abl
EP2631248A3 (fr) Traitement de tumeurs à l'aide d'un anticorps anti-L1 spécifique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06816031

Country of ref document: EP

Kind code of ref document: A2